To join the phase 2 POSTPONE trial investigating pacritinib for advanced prostate cancer, patients must have metastases that are strongly positive for STAT5 activation—specifically, a recent tumor biopsy must show detectable nuclear STAT5 in more than 5% of cancer cells. This trial is built upon robust laboratory and clinical findings showing that the JAK2-STAT5 pathway […]
A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]
A first-in-human clinical trial conducted at The University of Texas MD Anderson Cancer Center has revealed encouraging early results for HLD-0915, a new oral therapy designed for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that HLD-0915 is well tolerated and […]
The investigational drug ENV-105 (carutoximab), a first-in-class CD105 antagonist, has shown promising interim efficacy results in a Phase 2 clinical trial involving patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after standard hormone therapies. This ongoing trial evaluated the combination of ENV-105 with apalutamide, a commonly used hormone therapy. Among patients treated, 86% […]
Gedatolisib, an inhibitor targeting the PI3K/AKT/mTOR pathway, in combination with darolutamide, an androgen receptor antagonist, is being evaluated as a treatment option for metastatic castration-resistant prostate cancer (mCRPC). In a phase 1/2 clinical trial, patients who had progressed on prior androgen receptor signaling inhibitors received once-weekly intravenous gedatolisib in doses of 120 mg or 180 […]
A novel therapeutic approach combining lutetium-177 177Lu-PSMA-I&T and radium-223 (223Ra) shows encouraging results for men with metastatic castration-resistant prostate cancer (mCRPC), as demonstrated in the recently reported AlphaBet trial published in The Lancet Oncology in October 2025. This phase 1/2 AlphaBet study is the first to evaluate the safety, feasibility, and preliminary efficacy of the […]
At the 2025 ESMO Congress, new data from the phase 1/2 PETRANHA trial introduced saruparib (AZD5305), a highly selective PARP1 inhibitor, as a potentially safer and more effective therapeutic partner for androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. The results highlighted a strong efficacy signal in castration-sensitive disease and ARPI-naïve castration-resistant settings, while […]
The phase 2 Co-PSMA trial conducted at St Vincent’s Hospital in Sydney evaluated 64Cu-SAR-bisPSMA, a novel copper-based PET imaging agent, against the standard 68Ga-PSMA-11 tracer in patients with biochemical recurrence of prostate cancer and low PSA levels. Results showed 64Cu-SAR-bisPSMA detected a statistically greater number of PSMA-positive lesions per patient than the standard agent, particularly […]
This Phase II study explores a novel approach to treating metastatic hormone-sensitive prostate cancer (mHSPC) through PSA-triggered intermittent therapy. Traditionally, men with mHSPC are managed with continuous androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors (ARPIs). This strategy has significantly extended survival but often leads to enduring side effects such as fatigue, […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy